Workflow
血友病基因治疗产品
icon
Search documents
新华财经晚报:9部门发文支持一刻钟便民生活圈建设扩围升级
Xin Hua Cai Jing· 2025-09-19 13:52
Domestic News - The Ministry of Commerce and nine other departments announced 20 measures to promote the expansion and upgrade of the "15-minute convenient living circle" by 2030, aiming to establish 100 pilot cities and create 10,000 well-structured living circles with a resident satisfaction rate of over 90% and a chain store rate of over 30% [1] - The Ministry of Ecology and Environment reported that China has built the world's largest carbon emissions trading market, covering over 60% of the country's carbon emissions, and has initiated a voluntary greenhouse gas reduction trading market [1] - The Ministry of Industry and Information Technology, along with other departments, issued a "Light Industry Stabilization Growth Work Plan (2025-2026)" to enhance the role of light industry in economic stability, with a focus on new growth points such as smart home products and sports leisure products [2] - The Ministry of Transport released a plan to build high-quality data sets for the transportation industry by 2030, aiming to improve data supply and support the development of intelligent transportation networks [2] - The Civil Aviation Administration reported that China's civil aviation achieved a total transportation turnover of 151.8 billion ton-kilometers in August, marking a year-on-year increase of 8% [3] Market Updates - The People's Bank of China announced adjustments to the 14-day reverse repurchase operations, which will now be conducted with fixed quantity and interest rate bidding [3] - The National Foreign Exchange Administration reported that in August 2025, banks settled 15,103 billion yuan and sold 14,058 billion yuan, with cumulative settlements from January to August reaching 113,938 billion yuan [3] - The China Automobile Industry Association is conducting an anti-discrimination investigation in response to the U.S. measures against China's integrated circuit sector, focusing on the impact on the automotive industry [4] Housing and Automotive Industry - Shanghai has optimized its housing property tax pilot policies, providing tax exemptions for high-level talents and first-time homebuyers under certain conditions [5] - Xiaomi Auto Technology has initiated a recall of 116,887 electric vehicles produced between February 6, 2024, and August 30, 2025, in compliance with regulations [5]
我国创新药上半年对外授权近660亿美元
Yang Shi Xin Wen· 2025-09-19 08:46
Core Insights - The National Medical Products Administration (NMPA) of China has approved 56 innovative drugs in 2025, including 18 biopharmaceuticals, marking a significant advancement in the field of biomedicine [1][2] - Biopharmaceuticals are at the forefront of the contemporary biomedicine technology revolution, providing new treatment possibilities for major and rare diseases [1] - The average review time for clinical trials of innovative drugs has significantly decreased, from 175 working days in 2017 to 50 working days in 2024, and the review time for drug listing applications has reduced from 420 working days to 235 working days in the same period [1] Summary by Categories Innovative Drug Approvals - In 2025, 56 innovative drugs have been approved in China, with 18 being biopharmaceuticals, including the first stem cell therapy product and the first gene therapy product for hemophilia [1] - In 2024, 48 innovative drugs were approved, with biopharmaceuticals accounting for 22 of them, representing 45.8% of the total [1] Clinical Trial and Review Efficiency - The NMPA has accelerated the approval process for urgently needed and innovative products, significantly reducing the average review time for clinical trials and drug applications [1] Research and Development Landscape - China has 2,400 advanced therapy drugs in the research pipeline, indicating a substantial increase in R&D activity [2] - China has been elected as a member of the International Council for Harmonisation (ICH) three times, implementing 71 ICH guidelines, which enhances the synchronization of drug development and approval processes [2] - The total amount of innovative drug licensing transactions from China in the first half of 2025 reached nearly $66 billion, surpassing the total of $51.9 billion for the entire year of 2024 [2]